Objectives/Hypothesis: To review the known histopathologic findings and clinical behavior of mammary analogue secretory carcinoma (MASC).
INTRODUCTION
Mammary analogue secretory carcinoma (MASC) is a rare salivary gland tumor that recapitulates the histology and genetics of an equally rare malignancy of the breast, secretory carcinoma (SC). 1 SC is a slow-growing, low-grade ductal breast carcinoma that occurs in adolescent women and, occasionally, in elderly women. 2, 3 The tumor is defined by the t(12;15)(q13;q25) translocation, a fusion of the ETV6 gene from chromosome 12 and the NTRK3 gene from chromosome 15. The fusion results in a constitutively active chimeric tyrosine kinase and probable activation of the Ras-MAP kinase mitogenic pathway and the phosphatidyl inositol-3-kinase-AKT pathway. 4, 5 The same translocation was first detected in infantile fibrosarcoma and congenital mesoblastic nephroma. 6, 7 In 2010, Skalova et al. reviewed the pathology of 16 salivary gland tumor cases previously classified as either acinic cell carcinoma (AciCC) or ADC-NOS. 1 The authors noted histological features, in particular the absence of zymogen granules, strong staining for mammaglobin, and the presence of abundant extracellular colloid-like material, which prevented easy classification by the existing pathological definitions of known salivary gland tumors. After noting features similar to SC of the breast, the authors found that 15 of these cases also tested positive for the ETV6-NTRK3 translocation via FISH. MASC became one of many salivary gland tumors with a breast tumor analog, including pleomorphic adenoma (PA), mucoepidermoid carcinoma (MEC), and AciCC. 3 In the last 2 years, 90 cases of MASC have been published (see Table I ). 1, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Most are derived from the retrospective review of institutional archives of other salivary gland tumor diagnoses. Bishop et al. recently reported that 19% of parotid gland and 79% of extraparotid gland tumors originally diagnosed as AciCC were reclassified as MASC. 8 While MASC's histological features have been studied extensively in the pathology literature, its clinical behavior is largely uncharacterized. In this review, we seek to consolidate existing knowledge and encourage new research on the diagnosis and management of this increasingly important salivary gland malignancy.
MATERIALS AND METHODS
For this contemporary review, we conducted a PubMed search of the terms "mammary analogue secretory carcinoma," "mammary analog secretory carcinoma" and "MASC." We included both English and foreign-language publications, if available in translation. We identified 18 original case reports or case series and one review in a pathology journal. 1, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Two case series were from Japan and Korea; 16, 17 the remaining publications were from the United States. Patients from all publications were combined in order to generate overall demographic descriptions of patients with this rare tumor; we did not double count patients reported in more than one publication. 10, 11, 14, 15, 19 Survival meta-analysis was not attempted due to a recently published attempt 10 and variably reported and limited followup. FISH analysis for this case was performed by the cytogenetics laboratory at Brigham and Women's Hospital (Boston, MA), using the Vysis LSI ETV6 (TEL) (12p13) dual-color, break-apart rearrangement probe (Abbott Molecular, Chicago, IL) according to manufacturer guidelines. The probe set labels the telomeric 5 0 end of ETV6 red, and the flanking centromeric 3 0 region green. Probe signals were evaluated in 50 nonoverlapping metaphase cells, with 19/50 (38%) nuclei exhibiting a split probe signal, indicating rearrangement of the ETV6 gene. 
DISCUSSION

Histopathology and Cytopathology
On gross inspection, MASC is generally a solitary, well-circumscribed, and often encapsulated mass that is brown or gray in color and rubbery in texture. 1, 9, 17, 18 The central histologic features include:
Cystic, tubular, solid and/or papillary architecture 9, 11, 17 Eosinophlic vacuolated cytoplasm 9, 11, 12, 17 Intraluminal and/or intracellular colloid-like secretions that stain positive for periodic acid Schiff (PAS) and are diastaseresistant 1, [11] [12] [13] 17, 20, 23, 24 Low-grade, bland, and pale nuclei 12, 17 Positive staining for S-100 1, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Positive staining for mammaglobin, a uteroglobin protein identified in breast tissue, endometrial cancer, and sweat gland carcinomas 1, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The defining cytogenetic characteristic of this lesion is the presence of the t(12;15)(q13;q25) ETV6-NTRK3 translocation, which has been established in reported cases by FISH, 1, 10, 12, 15, [17] [18] [19] reverse transcriptionpolymerase chain reaction (RT-PCR), 13, 23 or both. 12, 17, 19, 24 For labs utilizing RT-PCR for the identification of ETV6 translocations, the 110-bp fusion transcript of the ETV6-NTRK3 can be amplified and detected using the published transcript primer pioneered for congenital fibrosarcoma. 7 As RT-PCR allows for the amplification of short and scarce transcripts, the technique should be very sensitive. Petersson et al. reported a case in which the fusion transcript could not be detected by RT-PCR, but 47 of 100 nuclei exhibited a split signal on ETV6 FISH analysis. 24 Skalova et al. similarly reported one case (of 14 tested) that was negative for the fusion transcript and not analyzable by FISH analysis; the case was speculated to be the result of a low level of fusion transcript expression. In the same series, all tested cases (11/11) were positive for ETV6 gene rearrangement on FISH. 1 It is possible that the FISH probe, which detects ETV6 gene rearrangement but is not specific to a fusion partner, carries a greater sensitivity for subtler genetic variants of MASC. 24 More research is needed as few studies have performed both techniques on the same cases. were the first to observe a p63-positive basal cell layer encircling some areas of tumor, which could represent intraductal extension or possibly a ductal epithelial origin for this tumor. 10, 12 Aggressive features are uncommon, although extracapsular/extraglandular extension and perineural invasion (PNI) have been reported in several cases. 12 Jung et al. in 2013 have reported the only case of "dedifferentiation" or transition into high-grade histology; the authors described a sample with high-grade cellular and nuclear characteristics, solid and microcystic growth pattern, and comedonecrosis, all features reminiscent of high-grade de-differentiated acinic cell carcinoma. 17 Cytopathology reveals similar features as histopathology, including moderately cellular sheets of S100-positive cells arranged in papillary, cystic, tubular, and solid growth arrangements. 9, 15, 20, 21 Distinguishing between MASC and other common salivary gland tumors, or even normal salivary gland tissue, is more difficult in the context of aspirated tissue. Griffith et al., use cellularity to distinguish between tumor tissue and normal tissue. The authors also identify cytoplasmic vacuolation and acinar group size variations as key findings in aspirates of MASC. 15 Levine et al. found that MASC's characteristic cytological feature was the abundant extracellular material, which the authors describe as "bright metachromatic strings." 20 ETV6 FISH testing has been performed successfully on cell block material, including the case presented here, although one reported case did not have enough cells available for testing. 15 The major differential diagnosis of MASC includes AciCC, low-grade MEC, low grade cribriform cystadenocarcinoma (LGCC), and ADC-NOS. In 2012, Chiosea et al. reviewed 337 cases of salivary gland malignancy including AciCC, MEC, ADC-NOS, signet-ring adenocarcinoma, LGCC, low-grade sinonasal nonintestinal type adenocarcinoma (non-ITAC), and polymorphous low-grade adenocarcinoma (PLGA) diagnosed at their institution between 1956 and 2011. The most common malignancies reclassified as MASC were ADC-NOS (14/37) and AciCC (11/89); MEC (1/165) and LGCC (0/13) were uncommon. 10 The primary histologic and cytopathological features of MASC, AciCC, and low-grade MEC are listed in Table II . AciCC are histologically diverse: Samples contain intercalated, clear, and nonspecific glandular cells arranged in solid, microcystic, papillary-cystic, and follicular growth patterns. 1, 11 There is considerable overlap between AciCC and MASC, as both exhibit acinar differentiation and intercalated duct-type cells. A major point of distinction is the presence of blue-purple cytoplasmic zymogen granules, a sign of serous acinar differentiation, in AciCC. 10, 11 In 2012, Chiosea et al. identified 17 "zymogen-poor" cases of AciCC from institutional archives. Of these, 10 were reclassified as MASC. This has led some recent publications to suggest FISH testing on any "zymogen granule poor" AciCC. In addition, MASC stains more reliably for S100; AciCC is not positive for mammaglobin; and intercalated ducts and mucin production are features in MASC, but not in AciCC. [10] [11] [12] 14, 15 Finally, relative to AciCC, MASC is more likely to occur in men and at a location outside of the parotid gland. 10 Mucin production and occasional differentiation into serous cells may lead to diagnostic confusion between MASC and MEC. However, MASC does not contain the combination of goblet-type mucous cells, intermediate and squamoid/epidermoid cells characteristic of MEC. 8, 10, 15, 19, 20 In addition, MEC can harbor its own set of distinctive translocations: CRTC1(MECT1)-MAML2 and less frequently CRTC3-MAML2 or EWSR1-POU5F1. 10, 19, 20, [25] [26] [27] While MEC is nearly always positive for p63, S100 staining is uncommon. 15, 28 Of the 15 tested cases of LGCC, none have been reclassified as MASC. 10, 12 LGCC shares S100 positivity with MASC. In addition, according to an unpublished finding cited by Laco et al., LGCC may also stain for mammaglobin and STAT5a, as for AciCC. 1, 23 On histological examination, MASC and LGCC can be distinguished by the more extensive ductal involvement and apocrine morphology in LGCC. 12 
Clinical Presentation and Diagnosis
Ninety-two cases of MASC, including the case presented at the beginning of this review, have been reported in the literature. Although several case series have noted a male predominance, 1,10,11 reported cases are divided fairly evenly by gender: 51 (55%) are male and 41 (45%) are female. The average age was 44.2 years (range, 14 to 77). Four patients were under the age of 18 years. The majority (71%) of tumors were located in the parotid gland, while the remainder occurred in a large diversity of locations, including the submandibular gland (7%), soft palate, buccal mucosa, base of tongue, and lips. In the nine series that reported tumor dimensions, the average tumor size was 1.98 cm (range, 0.5 to 5.5 cm). 1, 9, 12, [16] [17] [18] [20] [21] [22] [23] [24] 29 Presenting symptoms have been described in 59 patients, including the case at the beginning of this review. 1, 10, 12, 16, [20] [21] [22] [23] [24] The most common presentation is a slowly enlarging and painless nodule, often detected incidentally on physical examination. Only one patient presented with facial paralysis from a bulky parotid gland tumor. 10 Combining the 23 patients with detailed symptom timing, the median duration of symptoms is 4.25 years (range, 2 months to 30 years). 1, 12, 16, [20] [21] [22] Although the disease follows an indolent course in most patients, one reported patient presented after rapid growth of a 5.5 cm parotid gland nodule within 2 months. The patient, who had regional metastases to cervical nodes at diagnosis, went on to develop distant metastases and died of the disease.
The appearance on imaging has been described in three patients. On ultrasound, the lesion appeared hypoechoic and solid in two patients. 20, 21 On CT with contrast, a single patients' lesion was well-circumscribed and mildly enhancing. On MRI, an intraparotid lesion exhibited hyperintensity relative to muscle on T1, and hypointensity relative to the parotid gland on T2. 16 In our case, we found a similarly hyperintense and enhancing T1 appearance, but we also detected hyperintensity in T2 (see Fig. 1 ).
Fine needle aspiration is an appropriate adjunct to imaging, as in most salivary gland tumors. Although the cytopathological findings on FNA may not be distinctive, recent reports have described preparation of cell blocks that can undergo immunohistochemistry and FISH analysis for the ETV6-NTRK3 translocation. 9, 15 Of the 12 fine needle aspirate cases described in the literature, only one received the initial diagnosis of MASC. 9, 15, 20 Surgical extirpation may be required for definitive diagnosis.
Progression and Survival
Reported cases of MASC encompass a broad range of clinical behaviors, from indolent to aggressive. In the largest estimate of the risk of progression and death, Chiosea et al. followed 14 patients from the authors' institutional cohort, and 14 additional patients culled from the literature. 1 The mean disease-free survival, using death or recurrence as the end-point, was 92 months (95% CI, 71-115). In contrast, among 38 cases with conventional AciCC, the mean survival was 121 months (95% CI, 92-149); the difference was not statistically significant (P 5 0.43). Jung et al. followed nine patients. 17 Of these, three developed local recurrence at a median time of 44 months (range, 10-101). Overall, among all 91 reported cases, only four cases of death from disease have been reported, although survival data is variably reported and follow-up is minimal. Two of those cases followed the only two reports of distant metastasis. The third case followed multiple locoregional recurrences, and the fourth case followed unspecified recurrence. 1, 10 Patients with MASC may be more likely to have a higher T (primary tumor) stage at diagnosis than patients with AciCC, though no statistical comparison has been published to support this observation. 10 Of the 65 patients with known T stage reported in the literature, 38 (58%) were T1, 13 (20%) were T2, 11 (17%) were T3, and three (5%) were T4. 1, 10, 17, 20, 22 The risk for regional nodal disease at diagnosis may also be higher in patients with MASC than in patients with AciCC. In an observation that has been widely cited, Chiosea et al. found that 4 of 18 (22%) patients with MASC who underwent neck dissection were found to have disease involvement of nodes. 10 In contrast, only 3 of 38 (7.9%) of patients with AciCC who underwent neck dissection were found to have disease involvement of nodes. While this difference was statistically significant, the significance was lost when Chiosea et al. included seventeen additional cases with known nodal status from previous reports, though the proportion of MASC patients with nodal involvement (6/34 or 17.6%) remained higher than AciCC.
The observed clinical behavior of reported cases of MASC may have been skewed by the focus on testing malignant salivary gland tumors. Recently Williams et al. performed the first review of 12 benign (cyst) adenomas. 29 One encapsulated parotid tumor exhibited ETV6 gene rearrangement by FISH analysis. Future retrospective studies that include tumors previously diagnosed as benign may find the average behavior of the tumor is more indolent than currently perceived. These studies may also help to identify the features, such as the absence of encapsulation, that predict likelihood of nodal metastasis.
Disease outcomes in large cohorts of AciCC patients are well-known, but complicated by the probable presence of a subset of patients with MASC. [30] [31] [32] In 1991, Lewis et al. followed 90 patients with AciCC and found a 5-year overall survival (OS) rate of 90%, 10 year OS of 83%, and 20 year OS of 67%. 31 By crude calculation, 44% suffered local recurrence, 19% developed metastases, and 25% died of disease. Patients with high-grade AciCC faced a very poor prognosis; the majority developed nodal and distant disease and died of disease within 5 years. In 1983, Ellis et al. followed 244 patients with AciCC, and found a recurrence rate of 12%, a metastatic rate of 7.8%, and a death rate of 6.1%. 30 While histology did not have prognostic significance, the presence of a prominent intercalated duct component, a feature suggestive of MASC 19 , was the most common histology pattern observed in cases with metastatic disease.
Treatment
Of the 86 patients with known treatment details, all underwent varying degrees of surgical resection. At least 21 patients (26%) underwent neck dissections (ND). Seventeen patients (20%) received postoperative radiotherapy (PORT), and two patients received PORT and chemotherapy (agents unspecified) (2%). No reported patients have received RT without prior surgical resection.
The value of PORT is unclear due to the paucity of treatment-specific survival data. Skalova et al., in their initial report of 16 patients, found that of the seven patients who received PORT, one patient died of metastatic disease, one patient died after multiple local recurrences, three patients have no evidence of disease after locoregional recurrences, and two patients did not experience any disease progression. 1 In comparison, of the nine patients who did not receive RT, one patient suffered a local recurrence, one patient was lost to follow-up, and seven patients did not experience any disease progression. These two groups differed significantly, however, in the size of local disease, which makes comparison difficult. In addition, RT dose and field data were not reported.
Standard of care for low-grade malignant salivary gland tumors is radical surgical resection. PORT is reserved for close (<5mm) margins/incomplete resection, perineural invasion, and all T3 to T4 tumors. 33, 34 Doses between 60 Gy to66 Gy are delivered in fractions of 1.8 to 2 Gy for between 5 to 6 treatments per week. In 2005, Terhaard et al. reported outcomes after PORT in 386 patients, the largest cohort of mixed salivary gland tumor histologies, including AciCC, MEC, and ADC-NOS. 34 While PORT significant improved local control (LC) at 10 years (PORT vs. surgery alone; 91% vs. 76%; P 5 0.0005), patients with close or incomplete resection and advanced T stage benefited the most. Patients not meeting these criteria experienced adequate disease control (LC 95% at 5 years) with surgery alone. Primary RT alone, delivered to 70 Gy in fractions of 1.8 to 2 Gy, is given to tumors with unresectable or distant disease; in Terhaard et al., tumors that received 66 Gy had a LC of 50% at 5 years. 34 There are no straightforward indications for ND, though the risk of nodal disease is known to depend on T stage, histology (least likely for AciCC, adenoid cystic carcinoma, and carcinoma ex-pleomorphic adenoma; most likely for squamous cell and undifferentiated carcinoma) and location (most likely for submandibular gland). 34 Terhaard et al. and Al-Mamgani et al. recommend ND for all high-risk patients (all T3-T4, stage T2 MEC, Stage T1-T2 squamous cell/undifferentiated carcinoma) and for patients with clinical nodal disease. 33, 34 PORT to the neck, delivered to doses between 50 and 54 Gy in fractions of 1.8 to 2 Gy, is reserved for patients with confirmed pathological nodal disease. 33, 34 Overall, there is no conclusive evidence that MASC should be treated any differently than other low-grade malignant salivary gland cancers. Surgeons may be more likely to consider neck dissection and/or neck radiotherapy in patients with MASC given limited available data. However, the increased propensity for regional lymph node metastases is based on retrospective review of a very small group of patients managed with variable methods. 10 
CONCLUSION
MASC is a newly recognized malignant salivary gland tumor distinct from acinic cell carcinoma that mimics the histology and genetics of SC of the breast. Although it appears to follow an indolent course in most patients, certain cases appear predisposed to distant metastasis and increased mortality. Currently there is no way to predict which tumors will behave aggressively. There is a growing body of data on this disease in the pathology literature; however, it is not a commonly described entity in the otolaryngology community. Further research is needed to understand the clinical behavior and prognostic significance of MASC. Indeed, large-scale retrospective analysis of existing salivary gland carcinoma tissue may help to answer this question.
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